Polycystic Kidney Disease Assay At Cornell University Uses Transgenomic’s Surveyor Nuclease & WAVE Technology
Saturday, April 4th, 2009Transgenomic, Inc. (OTC Bulletin Board: TBIO). In a peer-reviewed paper published in the February 2009 issue of the journal Human Mutation, a team at Weill Cornell Medical College New York describes in detail the key advantages of using Transgenomic’s Surveyor Nuclease technology for mutation scanning of PKD1 and PKD2, two important genes used in the diagnosis and prognosis of autosomal dominant polycystic kidney disease (ADPKD).
Lees meer..